Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05763459 | A Phase 1 Study of ABBV-CLS-7262, Rosuvastatin, and Digoxin in Healthy Subjects | PHASE1 | COMPLETED | 12 | — | — | Mar 24, 2023 | Jun 2, 2023 | Jun 26, 2023 | 1 | United States |
Area under the Curve (AUC)
Area under the Curve (AUC)
| Arm | Type | Description |
|---|---|---|
| ABBV-CLS-7262 | EXPERIMENTAL | ABBV-CLS-7262 + Digoxin + Rosuvastatin |
| Name | Type | Description |
|---|---|---|
| ABBV-CLS-7262 | DRUG | Drug: ABBV-CLS-7262 Drug: Digoxin Drug: Rosuvastatin |
Inclusion Criteria: * Adult volunteers in general good health * Must voluntarily sign and date an informed consent, approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study-specific procedures * Individuals between 18 and ...